

BUSINESS NEWS – 18th August 2021

[Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® \(tazemetostat\) in Greater China](#)

“We are thrilled to be able to launch this collaboration designed to bring TAZVERIK® to patients in Greater China and to have HUTCHMED participate in the global development of TAZVERIK®,” commented Mr. Robert Bazemore, Epizyme President and CEO. “HUTCHMED is an ideal partner for us in Greater China, given their development and commercial expertise and shared commitment to expanding the value of TAZVERIK® through new clinical trials that complement Epizyme’s development plans.” Mr. Bazemore continued, “Through this collaboration we anticipate TAZVERIK® to become the first EZH2 inhibitor brought to market in Greater China, and we believe the involvement of HUTCHMED in the global development of TAZVERIK® can allow for a more rapid, resource-efficient, and geographically inclusive development plan for the U.S. confirmatory EZH-302 trial of TAZVERIK® in second line follicular lymphoma (2L FL) in combination with Revlimid plus rituximab (‘R²’).”

[Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin](#)

“This collaboration leverages Seagen’s world-class expertise and knowledge of ADC development, manufacturing and commercialization to maximize the potential of disitamab vedotin. It also complements our existing franchises and our deep and diverse portfolio of innovative anti-cancer therapies for patients in need,” said Clay Siegall, Ph.D., President and CEO, Seagen. “The addition of disitamab vedotin as a late-stage asset with multiple development opportunities aligns strategically with our plans to continue expanding our global footprint and deliver meaningful therapies to patients around the world.”

[Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies](#)

“Our strategy for developing precision oncology therapies, along with the capital raised from this transaction, positions us well to advance our lead programs into the clinic, developing potentially transformational therapies for genetically-defined patient populations,” said Dr. Weber. “I want to again thank the many people involved in making this transaction a success, including our new and existing investors, and the Tango, Boxer and BCTG teams.”